A first-in-class dual CD28/ICOS antagonist

ALPN-101 is a first-in-class dual inhibitor of the CD28 and ICOS T cell costimulatory pathways being developed for treatment of severe inflammatory diseases. Leveraging our proprietary scientific platform, our scientists engineered a single protein domain, or vIgD (Variant Ig Domain) based on human inducible T cell costimulator ligand (ICOSL) that is capable of binding to both CD28 and ICOS. By simultaneously blocking two key costimulatory pathways, ALPN-101 has the potential to improve outcomes in patients suffering from severe autoimmune/inflammatory disease.

In June 2020, we signed an exclusive worldwide option and license agreement with AbbVie for ALPN-101. Under the terms of the agreement, we received an upfront payment of $60 million, and will also be eligible to receive up to an aggregate of $805 million for exercise of the option and success-based development, regulatory and commercial milestones. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for ALPN-101.

ALPN-101 completed enrollment of a Phase 1 healthy volunteer study in October 2019. Final data were presented at the 2020 EULAR E-Congress. The key findings presented are summarized below:

  • No infusion-related, hypersensitivity, or allergic reactions
  • No cytokine storm or release (CytokineMAP A&B)
  • No grade 3+ adverse events
  • Most common adverse events were self-limited upper respiratory tract infections and headaches

ALPN-101 is currently enrolling Synergy, a Phase 2 study of ALPN-101 in patients with Systemic Lupus Erythematosus (SLE).  For more information on our ongoing clinical trials please refer to the Clinical Trials portion of our website.

For additional information please refer to our corporate filings, corporate presentation, and Scientific Publications.

ALPN-101: A First-in-Class Dual CD28/ICOS Antagonist
for Multiple Inflammatory Disease Indications

ALPN-101 Schematic